Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Janice Chen, Christopher L. Brooks, Peter McDonald, Jonathan D. Schwartz, Keiichi Sakakibara, Naoya Saito...Takuji Sato, Takumi Kawabe, Eric Keith Rowinsky
Title Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers
Journal Journal of Clinical Oncology
Abstract Text Journal of Clinical Oncology 33, no. 15_suppl


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
SL-801 SL-801 1 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
SL-801 SL-801 is a small molecule inhibitor of XPO1, which prevents substrates from binding to XPO1, thereby disrupting the nuclear export of proteins, and thus, may lead to inhibition of tumor growth (Journal of Clinical Oncology 33, no. 15_suppl).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable SL-801 Preclinical - Cell line xenograft Actionable In a preclinical study, SL-801 resulted in tumor growth inhibition in xenograft models with various advanced solid tumors (Journal of Clinical Oncology 33, no. 15_suppl). detail...